In the last few years, “personalized medicine”— using genetic or other molecular biology-based diagnostic tests to customize treatment for a particular patient — has emerged as a powerful new tool for health care.
Therapy guided by genetic testing has proven highly successful in treating some types of leukemia and breast and lung cancer. Similar “personalized” therapies are on the horizon for other types of cancer, as well as diabetes, heart disease and other deadly disorders.
Now, University of Texas Medical Branch at Galveston (UTMB) researchers and their colleagues elsewhere have taken the first steps toward bringing the methods of personalized medicine to asthma.
Applying state-of-the-art protein screening techniques to samples taken from 84 asthmatic volunteers, they’ve made the first identification of different subtypes of asthma based on distinct “protein profiles,” unique combinations of 10 or more proteins with which they are associated.
One of these profiles corresponds to a variety of severe, treatment-resistant asthma that, while rare, is responsible for 40 to 50 percent of the total health care costs associated with the disease.
“We know that in asthma some people respond to very specific types of therapies and others don’t,” said Dr. Allan Brasier, director of UTMB’s Sealy Center for Molecular Medicine and a senior author of a paper on the study appearing in the just-published January issue of the Journal of Allergy and Clinical Immunology (online at
http://journals.elsevierhealth.com/periodicals/ymai). “Being able to discover different asthma subtypes should allow us to tailor our treatments to increase the odds of a positive response,” Brasier added.
To obtain their samples, researchers squirted a small amount of saline solution through tiny tubes into the anesthetized volunteers’ lungs. They then sucked the saline back out, bringing with it proteins washed free from walls of the network of air passages and sacs in the lungs (which swell closed when they are inflamed during an asthma attack).
“In each sample, we measured 25 different cytokines, inflammatory signaling proteins that play a very important role in asthma,” Brasier said. “We found that our samples fell into one group associated with severe asthma, another group that looks like it represents less severe disease, and two additional groups whose significance we don’t yet understand.”
The unknown protein profiles, Brasier said, could be produced by types of asthma that respond differently to treatment, or that are generated by different genetic or environmental sources. These and other as-yet-undiscovered protein patterns may eventually be used to diagnose types of asthma aggravated by cigarette smoke, for example, or that cause a steady decline in lung function over a number of years.
“Until now, all we knew was that asthma was a disease that manifested itself in many different ways,” Brasier said. “By using these patterns of multiple different proteins, we can start defining those different subtypes much more accurately — which is very useful for trying to identify which ones will respond to which treatments.”
According to Brasier, clinical applications of asthma protein profiling will have to await the discovery of additional protein patterns to match with other subtypes of asthma, as well as more sensitive tests that would allow for less invasive sampling techniques—a blood test, for example, or an analysis of exhaled breath.
“We’re still a little bit away from treating people, but that’s coming,” Brasier said. “This is the proof of principle that you can apply proteomic patterns to personalized medicine in asthma.”
Source: University of Texas Medical Branch at Galveston
Related stories:
Researchers define characteristics, treatment options for XXYY syndrome
Researchers at the UC Davis M.I.N.D. Institute and The Children's Hospital in Denver have conducted the largest study to date describing the medical and psychological characteristics of a rare genetic disorder in which males have two "X" and two "Y" chromosomes, rather than the normal one of each. The study, published in the June 15, 2008, issue of the
American Journal of Medical Genetics Part A, also offers treatment recommendations for men and boys with the disorder.
Life under the laser
Researchers at The University of Nottingham have developed a unique technology that will allow scientists to look at microscopic activity within the body's chemical messenger system for the very first time, live as it happens.
Seeing through tooth decay
Dental caries afflict at least 90% of the world's population at some time in their lives. Detecting the first signs of this disease, which can be lethal in extreme cases, just got easier thanks to work by researchers in India discussed in the latest issue of the
International Journal of Biomedical Engineering and Technology.
White Blood Cell Uses DNA 'Catapult' to Fight Infection
(PhysOrg.com) -- U.S. and Swiss scientists have made a breakthrough in understanding how a type of white blood cell called the eosinophil may help the body to fight bacterial infections in the digestive tract, according to research published online this week in
Nature Medicine.
It's The Water: Beijing Olympic Swimmer Provided State-of-Art ProMinent Ozone Technology
(PhysOrg.com) -- As Olympic records are being broken left and right by Michael Phelps, questions have been raised do we have a performance enhancing water issue. Some attribute the gold hanging around Olympiad Phelps is the result of a Superman fabric developed by Speedo. In fact, aside from a truly phenomenal performances by the swimmers, it could be the water. ProMinent, the brainchild of Professor h.c. Viktor Dulger in Heidelberg developed the first electronic solenoid driven dosing pump known as the Ozone Technology system for sanitizing pools in 1971. The system does not rely on chlorine which is viewed as harmful to swimmer's lungs, eyes and may cause skin rashes. ProMinent is a leader world-wide with operations in China, Germany, Hungary and South America.
Novel study finds proton channels inhibit the release of histamine during allergic reactions
Inhibiting the proton currents in basophils, a rare type of white blood cell, can stop the release of histamine and could provide a new target for allergy and asthma drugs according to a new study by researchers at Rush University Medical Center in Chicago and the Johns Hopkins Asthma and Allergy Center in Baltimore. The research is published in the August 5th issue the
Proceedings of the National Academy of Sciences.
New study sheds light on how intracellular pathogens trigger the immune system
(PhysOrg.com) -- Disease-causing microbes like the food-borne bacterium Listeria monocytogenes specialize in invading and replicating inside their animal hosts' own cells, making them particularly tricky to defeat. Now, a new study led by biologists at the University of California, Berkeley, has identified a molecular alarm system in which the intracellular pathogen sends out signals that kick the immune response into gear.
Cancer therapies from the ocean?
Scientists from Aberdeen, Luxembourg and the South Pacific have studied the properties of natural products derived from animals found in Fijian waters, and shown that not only may certain compounds have potential use in anti-cancer therapies, but others may also be useful for improving drug delivery, currently one of the most significant problems faced by medical researchers.